Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Financings
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common Units (or Pre-Funded Units) of common stock and common warrants Announced: about US$4.3M · US$4.09 a unit · Warrants at US$3.96 for 60 months · Spartan Capital Securities, LLC Dealers: Spartan Capital Securities, LLC (lead) Use of proceeds: General corporate purposes and working capital | Dec 18, 2025 |
| Registered direct offering of shares of Common Stock (or Pre-Funded Warrants) Closed: US$1.5M raised · US$1.54 a share · Spartan Capital Securities, LLC Dealers: Spartan Capital Securities, LLC (lead) Use of proceeds: General corporate purposes and working capital | Jul 8, 2025 |
| Private placement of common stock (or pre-funded warrants), Series B convertible preferred stock and common warrants Closed: US$5M raised · Warrants at US$1 for 60 months · Spartan Capital Securities, LLC Dealers: Spartan Capital Securities, LLC (lead) Use of proceeds: General corporate purposes and working capital | Jul 2, 2025 |
| Registered direct offering of registered direct offering Closed: US$1.05M raised · US$2.415 a share · Warrants at US$2.29 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Mar 27, 2025 |
| Public offering of securities under Form S-1 registration statement Cancelled: public offering | Feb 10, 2025 |